Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

Epigenetic modifying enzymes such as histone deacetylases (HDACs), p300, and PRMT1 are recruited by AML1/ETO, the pathogenic protein for t(8;21) acute myeloid leukemia (AML), providing a strong molecular rationale for targeting these enzymes to treat this disease. Although early phase clinical asses...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Bots, Michael, Verbrugge, Inge, Martin, Benjamin P., Salmon, Jessica M., Ghisi, Margherita, Baker, Adele, Stanley, Kym, Shortt, Jake, Ossenkoppele, Gert J., Zuber, Johannes, Rappaport, Amy R., Atadja, Peter, Lowe, Scott W., Johnstone, Ricky W.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2014
Предметы:
Myeloid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3938147/
https://ncbi.nlm.nih.gov/pubmed/24415537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-03-488114
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы